Dergiler / Medicine Science / 2015 / Cilt: 4 - Sayı: 3

A Rare Cause of Hypercalcemia: “Immobilization”. A Case Report and Literature Review

Sayfa
2521–2527
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Physicians should be aware of this condition when seeing patients with restricted physical activity

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Immobilization hypercalcemia (IH) mainly results from rapid bone turnover and may be seen after spinal cord injury or long bone fracture in particular in children and adolescents.
📊
Temel Bulgular & Veri:A-19 year-old, male quadriplegic adolescent was referred to our outpatient clinic by a family physician.
💡
Sonuç & Katkı:Physicians should be aware of this condition when seeing patients with restricted physical activity
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Immobilization hypercalcemia (IH) mainly results from rapid bone turnover and may be seen after spinal cord injury or long bone fracture in particular in children and adolescents. The pathophysiology of this entity is entirely unknown. A-19 year-old, male quadriplegic adolescent was referred to our outpatient clinic by a family physician. At presentation he had some vague symptoms due to hypercalcemia including fatigue, nausea, vomiting, anorexia, constipation and dehydration. Laboratory investigations for hypercalcemia revealed low intact parathyroid hormone level, low 25-0H vitamin D, and high 24-hour urine calcium. He was diagnosed as having IH after all other causes of hypercalcemia were excluded. The pathophysiology of IH remains unclear. Treatment is directed towards lowering the serum calcium level. Up to date, intravenous hydration with isotonic saline, furosemide and salmon calcitonin have been the conventional therapies. Other treatment options include bisposphonates (such as etidronate, zoledronate or pamidronate) or, an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL), denosumab. IH is a rare cause of hypercalcemia. Physicians should be aware of this condition when seeing patients with restricted physical activity

🔖

Bu Makaleye Atıf Yap

ELBÜKEN, G., YAZİCİOGLU, B., ÖZTÜRK, O., DEMİRAĞ, M. D. (2015). A Rare Cause of Hypercalcemia: “Immobilization”. A Case Report and Literature Review. Medicine Science, Cilt: 4 - Sayı: 3, 2521–2527. https://ajindex.com/articles/277934

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Albright F, Burnett CH, Cope O, Parsons W. Acute atrophy of bone (osteoporosis) simulating hyperparathyroidism. J Clin Endocrinol. 1941;1:711-716
  2. Tori JA, Hill LL. Hypercalcemia in children with spinal cord injury. Arch Phys Med Rehabil. 1978;59(10):443-6
  3. Maynard FM. Immobilization hypercalcemia following spinal cord injury. Arch Phys Med Rehabil. 1986;67(1):41-4
  4. Meythaler JM, Korkor AB, Nanda T, Kumar NA, Fallon M. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Arch Intern Med. 1986;146(8):1567-71
  5. Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med. 1982;306(19):1136-40
  6. Benjamin RW, Moats-Staats BM, Calikoglu's A, Savendahl L, Chrysis D. Hypercalcemia in children. Pediatr Endocrinol Rev. 2008;5(3):778-84
  7. Naftchi NE, Viau AT, Sell GH, Lowman EW. Mineral metabolism in spinal cord injury. Arch Phys Med Rehabil. 1980;61(3):139-42
  8. Sato Y, Asoh T, Kaji M, Oizumi K. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res. 2000;15(12):2487-94
  9. Bikle DD, Halloran BP. The response of bone to unloading. J Bone Miner Metab. 1999;17(4):233-44
  10. Krieger NS, Sessler NE, Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol. 1992; 262(3 Pt 2):F442-8
  11. Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil. 1999;80(9):998-1000
  12. Gopal H, Sklar AH, Sherrard DJ. Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease. Am J Kidney Dis. 2000;35(5):969-72
  13. Gallacher SJ, Ralston SH, Dryburgh FJ, Logue FC, Allam BF, Boyce BF, Boyle IT. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate. Postgrad Med J. 1990;66(781):918-22
  14. Khairallah W, Fawaz A, Brown EM, El-Hajj Fuleihan G. Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Clin Pract Nephrol. 2007;3(7):397-404
  15. Gilchrist NL, Frampton CM, Acland RH, Nicholls MG, March RL, Maguire P, Heard A, Reilly P, Marshall K. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007;92(4):1385-90.